Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

AuthorManuela Pérez-Cebriánen
AuthorMaría M. Morales Suárez-Varelaen
AuthorIsabel Font-Nogueraen
AuthorEmilio Monte-Boqueten
AuthorJose Luís Poveda-Andrésen
AuthorJose María Martín-Morenoen
AuthorNuria Rubio-Lópezen
AuthorElias Ruiz-Rojoen
AuthorAgustín Llopis-Gonzálezen
Issued Date2015-07-31en
AbstractIndications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary.en
DOIhttps://doi.org/10.22037/ijpr.2015.1690en
KeywordApproval of indicationsen
KeywordDrug-related problemsen
KeywordDrug safety evaluationen
KeywordLinezolid prescriptionen
KeywordUniversity hospitalen
PublisherBrieflandsen
TitleStudy on the Linezolid Prescription According to the Approval of Indication in a University Hospitalen
TypeOriginal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijpr-14-857.pdf
Size:
582.56 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF